References
- DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200.
- Savarino E, Zentilin P, Marabotto E, et al. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18:1333–1343.
- Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37.
- Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22:20–24.
- Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009;49:444–454.
- Ahmed TA, El-Say KM. Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole. Life Sci. 2014;110:35–43.
- Sykes BW, Kathawala K, Song Y, et al. Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse. Equine Vet J. 2017;49:795–801.
- Dash RP, Rais R, Srinivas NR. Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview. Xenobiotica. 2018;48:422–432.
- Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27–36.
- Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739–2754.
- Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827.
- Liu R, Li P, Xiao J, et al. A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC-MS/MS: application to formulation development of the compound preparation of esomeprazole. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1068–1069:352–357.
- Liu F, Shokrollahi H. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. Int J Pharm. 2015;485:152–159.
- Srinivas NR. Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomed Chromatogr. 2009;23:451–454.
- Smeets-Peeters M, Watson T, Minekus M, et al. A review of the physiology of the canine digestive tract related to the development of in vitro systems. Nutr Res Rev. 1998;11:45–69.
- Jennifer BD. Comparison of canine and human gastrointestinal physiology, pharmaceutical research. Pharm Res. 1986;3(3):123–131.
- Viswanathan CT. Incurred sample reanalysis: a global transformation. Bioanalysis. 2011;3:2601–2602.
- Q1A(R2). Stability testing of new drug substances and products, ICH, Harmonised Tripartite Guideline, Current Step 4 version; 2003 Feb 6. p. 1–24.
- US FDA. Bioanalytical method validation guidance for industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Biopharmaceutics, May 2018. p. 1–44.
- Patel H, Patel P, Bhatt C, et al. Comparative pharmacokinetics of cholecalciferol in dogs from 2 different oral formulations using corrective measures to overcome interference from endogenous cholecalciferol. Drug Res (Stuttg). 2017;67:388–395.
- Aciphex/Rabeprazole Sodium, NDA-20973, Part 6, Page 73, Pharmacology Review, Center for Drug Evaluation and Research. [updated 1999 Aug 13; cited 2019 Jan 24]. p. 1–14. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20973_Aciphex_phrmr_P6.pdf